Puma Biotechnology — Third Quarter 2026 Earnings Summary

Puma Biotechnology reported third-quarter 2026 net income of $6.0 million, or $0.12 per diluted share, driven by $54.1 million in net product revenue from NERLYNX sales. The company raised its full-year 2026 net income guidance to a range of $20–$22 million, up from the previous forecast of $17–$20 million. Operating expenses increased year-over-year, primarily due to higher research and development costs associated with the alisertib clinical development program. Additionally, Puma initiated a new Phase II trial, ALISCA-Lung2, evaluating alisertib in combination with paclitaxel for advanced small cell lung cancer.